Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

YH 32367

Next Previous
Search
Drug Profile

YH 32367

Alternative Names: ABL-105; YH-32367; YH-32384

Latest Information Update: 15 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ABL Bio
  • Developer Yuhan
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 05 Apr 2024 Pharmacodynamics and adverse events data from a preclinical trial in solid tumour presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 01 Sep 2022 Yuhan Corporation plans a phase I/II trial(late staged disease, Metastatic disease) for Solid tumours in South Korea (NCT05523947)
  • 30 Jun 2022 Phase-I clinical trials in Solid tumours in South Korea (Parenteral) (Yuhan company pipeline,

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top